See more : Zhejiang Shibao Company Limited (002703.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Orchard Therapeutics plc (ORTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orchard Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Sun Hing Vision Group Holdings Limited (0125.HK) Income Statement Analysis – Financial Results
- Sichuan Haowu Electromechanical Co., Ltd. (000757.SZ) Income Statement Analysis – Financial Results
- Matterport, Inc. (MTTR) Income Statement Analysis – Financial Results
- Compeq Manufacturing Co., Ltd. (2313.TW) Income Statement Analysis – Financial Results
- Latin Metals Inc. (LMSQF) Income Statement Analysis – Financial Results
Orchard Therapeutics plc (ORTX)
About Orchard Therapeutics plc
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.99M | 483.00K | 2.60M | 2.51M | 2.08M | 0.00 | 0.00 |
| Cost of Revenue | 2.43M | 226.00K | 857.00K | 805.00K | 422.00K | 0.00 | 0.00 |
| Gross Profit | 4.55M | 257.00K | 1.74M | 1.71M | 1.65M | 0.00 | 0.00 |
| Gross Profit Ratio | 65.17% | 53.21% | 66.97% | 67.97% | 79.67% | 0.00% | 0.00% |
| Research & Development | 25.55M | 23.35M | 93.73M | 117.36M | 205.32M | 32.53M | 16.21M |
| General & Administrative | 44.66M | 49.65M | 56.89M | 49.16M | 0.00 | 5.99M | 3.00M |
| Selling & Marketing | 4.14M | 5.26M | 8.09M | 8.06M | 0.00 | 0.00 | 0.00 |
| SG&A | 10.60M | 13.55M | 64.99M | 57.22M | 31.37M | 5.99M | 3.00M |
| Other Expenses | 22.66M | 811.00K | 3.41M | 1.39M | 5.51M | -1.18M | 138.00K |
| Operating Expenses | 36.15M | 36.90M | 158.72M | 174.58M | 236.69M | 38.51M | 19.20M |
| Cost & Expenses | 38.58M | 36.90M | 159.57M | 175.39M | 237.11M | 38.51M | 19.20M |
| Interest Income | 857.00K | 63.00K | 3.19M | 7.36M | 0.00 | 0.00 | 3.00K |
| Interest Expense | 933.00K | 683.00K | 2.33M | 1.54M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.51M | 874.00K | 8.60M | 8.75M | 1.20M | 302.00K | 6.00K |
| EBITDA | -8.08M | -35.54M | -148.38M | -164.12M | -235.03M | -38.21M | -19.20M |
| EBITDA Ratio | -115.65% | -7,358.39% | -5,717.84% | -6,531.00% | -11,321.34% | 0.00% | 0.00% |
| Operating Income | -31.59M | -36.42M | -156.98M | -172.87M | -235.03M | -38.51M | -19.20M |
| Operating Income Ratio | -452.22% | -7,539.34% | -6,049.25% | -6,879.15% | -11,321.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.95M | -3.32M | 4.27M | 7.21M | 5.51M | -1.18M | 138.00K |
| Income Before Tax | -9.01M | -36.22M | -152.71M | -165.66M | -229.53M | -39.69M | -19.07M |
| Income Before Tax Ratio | -129.00% | -7,499.79% | -5,884.78% | -6,592.20% | -11,056.12% | 0.00% | 0.00% |
| Income Tax Expense | -1.13M | 125.00K | -731.00K | -2.24M | 970.00K | 53.00K | 20.00K |
| Net Income | -7.88M | -36.35M | -151.98M | -163.42M | -230.50M | -39.74M | -19.09M |
| Net Income Ratio | -112.84% | -7,525.67% | -5,856.61% | -6,503.06% | -11,102.84% | 0.00% | 0.00% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| Weighted Avg Shares Out | 12.80M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
Orchard Therapeutics to Present at Stifel's Genetic Medicines Day
Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Call Transcript
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
5 Hot Penny Stocks Exploding After News This Week
Orchard Therapeutics: Growing A Position In This Undervalued Gene Therapy Play
Orchard Therapeutics plc (ORTX) Q3 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports